Clinical Practice in the Alzheimer Biomarker Era-Drugs for the Brain and Care for the Mind

Jason Karlawish^{1

2

3}

Affiliations

¹ Perelman School of Medicine, Penn Memory Center, Department of Medicine, University of Pennsylvania, Philadelphia.
² Perelman School of Medicine, Penn Memory Center, Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
³ Perelman School of Medicine, Penn Memory Center, Department of Neurology, University of Pennsylvania, Philadelphia.

Comment

Jason Karlawish. JAMA Netw Open. 2023.

. 2023 Jan 3;6(1):e2250938.

doi: 10.1001/jamanetworkopen.2022.50938.

Jason Karlawish^{1

2

3}

¹ Perelman School of Medicine, Penn Memory Center, Department of Medicine, University of Pennsylvania, Philadelphia.
² Perelman School of Medicine, Penn Memory Center, Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
³ Perelman School of Medicine, Penn Memory Center, Department of Neurology, University of Pennsylvania, Philadelphia.

No abstract available

Comment on

Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
Caprioglio C, Ribaldi F, Visser LNC, Minguillon C, Collij LE, Grau-Rivera O, Zeyen P, Molinuevo JL, Gispert JD, Garibotto V, Moro C, Walker Z, Edison P, Demonet JF, Barkhof F, Scheltens P, Alves IL, Gismondi R, Farrar G, Stephens AW, Jessen F, Frisoni GB, Altomare D; AMYPAD consortium. Caprioglio C, et al. JAMA Netw Open. 2023 Jan 3;6(1):e2250921. doi: 10.1001/jamanetworkopen.2022.50921. JAMA Netw Open. 2023. PMID: 36637820 Free PMC article.

1. Caprioglio C, Ribaldi F, Visser LNC, et al.; AMYPAD consortium. Analysis of psychological symptoms following disclosure of amyloid-PET imaging results to adults with subjective cognitive decline. JAMA Network Open. 2023; 6(1):e2250921. doi:10.1001/jamanetworkopen.2022.50921 - DOI - PMC - PubMed
1. Grill J, Raman R, Ernstrom K, Sultzer D, Burns J, Donohue M, Johnson KA, Aisen PS, Sperling RA, Karlawish J: Short-term psychological outcomes of disclosing amyloid imaging results to research patients who do not have cognitive impairment. JAMA Neurol 2020; 77(12): 1504–1513. doi:10.1001/jamaneurol.2020.2734 - DOI - PMC - PubMed
1. Largent EA, Harkins K, van Dyck CH, Hachey S, Sankar P, Karlawish J: Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLoS One. 2020; 15(2): e0229137. doi:10.1371/journal.pone.0229137 - DOI - PMC - PubMed
1. Mozersky J, Sankar P, Harkins K, Hachey S, Karlawish J: Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults. JAMA Neurol 2018; 75(1): 44–50. doi:10.1001/jamaneurol.2017.2954 - DOI - PMC - PubMed
1. Largent EA, Stites SD, Harkins K, Karlawish J: That would be dreadful: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with others. J Law Biosci 2021; 8(1), lsab004. doi:10.1093/jlb/lsab004 - DOI - PMC - PubMed